Experimental drug combo targets tough brain cancers

NCT ID NCT07635173

Completed Disease control Sponsor: Shenzhen Zhenxing Medical Technology Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tested a new drug called obitazidine (SM-1) combined with the chemotherapy temozolomide in 35 adults with recurrent high-grade gliomas, a type of aggressive brain cancer. The main goal was to find a safe dose and check for side effects, while also looking for signs that the combination might shrink tumors. The study is complete but results are not yet reported.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Obitazidine fumarate (SM-1) combined with temozolomide
What this could lead to: If successful, this could point toward a new combination treatment option for patients with recurrent high-grade gliomas that have stopped responding to standard therapy.
What could go wrong: This is a very early Phase 1 trial with only 35 participants, focused on safety and dosing. It is too small to prove effectiveness, and the combination may cause serious side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMAS (GBM) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioblastoma glioma malignant glioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOBLASTOMAS (GBM) GLIOMA HIGH GRADE GLIOMAS

Contacts and locations

Locations

Beijing Tiantan Hospital, Capital Medical University

Beijing, Beijing Municipality, 100070, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.